Bildkälla: Stockfoto

Oncopeptides: Subscription rate 94% - Redeye

Redeye comments on the outcome of Oncopeptide's rights issue.

Redeye comments on the outcome of Oncopeptide's rights issue.
Börsvärldens nyhetsbrev
ANNONSER